Moreover, the advent of programmed cell death-1 (PD-1)/programmed cell death ligand-1 (PD-L1) has resulted in better prognostic outcomes of NSCLC patients (Jain et al., 2018). This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.